Clover Biopharmaceuticals, Ltd. (2197.HK)
HKD 0.26
(0.0%)
HKD 0.26
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | - CNY | -6.67% |
| 2022 | -2.44 Billion CNY | 59.33% |
| 2021 | -6.01 Billion CNY | -561.01% |
| 2020 | -909.92 Million CNY | -2278.83% |
| 2019 | -38.25 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -78.65 Million CNY | 80.87% |
| 2024 Q2 | -78.65 Million CNY | 0.0% |
| 2023 FY | -2.6 Billion CNY | -6.67% |
| 2023 Q2 | -880.24 Million CNY | 0.0% |
| 2023 Q1 | -880.24 Million CNY | -36.31% |
| 2023 Q4 | -411.2 Million CNY | 2.18% |
| 2023 Q3 | -420.36 Million CNY | 52.24% |
| 2022 Q2 | -554.34 Million CNY | 0.0% |
| 2022 Q1 | -554.34 Million CNY | 25.09% |
| 2022 FY | -2.44 Billion CNY | 59.33% |
| 2022 Q4 | -645.76 Million CNY | 0.0% |
| 2022 Q3 | -645.76 Million CNY | -16.49% |
| 2021 Q2 | -379.33 Million CNY | 0.0% |
| 2021 FY | -6.01 Billion CNY | -561.01% |
| 2021 Q4 | -740.01 Million CNY | 0.0% |
| 2021 Q3 | -740.01 Million CNY | -95.08% |
| 2021 Q1 | -379.33 Million CNY | 0.0% |
| 2020 FY | -909.92 Million CNY | -2278.83% |
| 2019 FY | -38.25 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 100.0% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 100.0% |